# "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma

> **NCT06590844** · PHASE4 · UNKNOWN · sponsor: **Anhui Provincial Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Injectable coenzyme I

## Key facts

- **NCT ID:** NCT06590844
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-19
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590844, ""cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06590844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*